Lucia Bio is a Queensland biotech joint venture between the UK’s Molecule to Medicine and the University of Queensland’s QEDDI. The company develops Syk inhibitors targeting autoimmune diseases and neuroinflammation, with lead assets QED-701 and QED-121. It recently topped up its seed round with an additional $2M, bringing total capital raised to $3M. The UniQuest Extension Fund and Uniseed-managed funds each contributed $1M to the extension. The article does not provide operating metrics, a valuation, or details of other financing instruments for Lucia Bio.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2025